TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis

Miki Kawai; Yuka Iijima-Yamashita; Iku Taguchi; Masato Kataoka; Masashi Sanada; Yoshiko Murakami; Chiyoe Kitagawa; Hiroyoshi Hattori

doi:10.12659/AJCR.936455

14 June 2022 : Case report Japan

TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis

Challenging differential diagnosis

Miki Kawai^1ADEF, Yuka Iijima-Yamashita^2CD, Iku Taguchi^1BD, Masato Kataoka^3ABE, Masashi Sanada^2CDEF, Yoshiko Murakami

^4BD, Chiyoe Kitagawa^5B, Hiroyoshi Hattori^1ADEFG*

DOI: 10.12659/AJCR.936455

Am J Case Rep 2022; 23:e936455

Authors information Article notes Copyright and License information

Background Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 2. Hematoxylin and eosin-stained gastric cancer biopsy sample. The estimated proportions of tumor cells, inflammatory infiltrates, and normal cells are 30–40%, 50%, and 10%, respectively.

Back to the Article

TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis

Your Privacy